Calm down when the heart is stressed: Inhibiting calmodulin-dependent protein kinase II for antiarrhythmias
1The Laboratory of Cardiovascular Phenomics, Center for Molecular Medicine, School of Medicine University of Nevada, Reno, NV; Department of Pharmacology, School of Medicine University of Nevada, Reno, NV.
Insights
Elevated calcium/calmodulin-dependent protein kinase II (CaMKII) signaling contributes to heart disease. Inhibiting CaMKII offers a therapeutic strategy for arrhythmias and heart failure.
Area of Science:
- Cardiovascular Medicine
- Molecular Cardiology
- Biochemistry
Background:
- Calcium/calmodulin-dependent protein kinase II (CaMKII) is crucial for cardiomyocyte function, regulating processes from electrical activity to survival.
- Elevated CaMKII signaling is implicated in cardiac remodeling during myocardial hypertrophy and ischemia.
Discussion:
- Increased CaMKII activity under stress contributes to ion channel remodeling and cardiac arrhythmias.
- Down-regulating CaMKII is a promising therapeutic approach for arrhythmias and heart failure.
Key Insights:
- CaMKII's role in cardiac pathophysiology is complex, involving multiple isoforms and downstream targets.
- Targeting CaMKII offers potential for treating diverse cardiac conditions.
Outlook:
- Developing specific CaMKII inhibitors is challenging due to pathway complexity.
- A systems-level understanding of CaMKII networks can accelerate the discovery of novel therapeutic agents.
Abstract:
Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) plays a pivotal role in many regulatory processes of cellular functions ranging from membrane potentials and electric-contraction (E-C) coupling to mitochondrial integrity and survival of cardiomyocytes. The review article by Hund and Mohler in this issue of Trends in Cardiovascular Medicine highlights the importance of the elevated CaMKII signaling pathways under stressed conditions such as myocardial hypertrophy and ischemia in the detrimental remodeling of ion channels and in the genesis of cardiac arrhythmias. Down-regulation of the elevated CaMKII is now emerging as a powerful therapeutic strategy for the treatment of cardiac arrhythmias and other forms of heart disease such as hypertrophic and ischemic heart failure. The development of new specific and effective CaMKII inhibitors as therapeutic agents for cardiac arrhythmias is challenged by the tremendous complexity of CaMKII expression and distribution of multi isoforms, as well as the multitude of downstream targets in the CaMKII signaling pathways and regulatory processes. A systematic understanding of the structure and regulation of the CaMKII signaling and functional network under the scope of genome and phenome may improve and extend our knowledge about the role of CaMKII in cardiac health and disease and accelerate the discovery of new CaMKII inhibitors that target not only the ATP-binding site but also the regulation sites in the CaMKII signaling and functional network.
More Related Videos
10:53Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
